CytoDyn Inc. is a clinical-stage biotechnology company. The Company is focused on the clinical development and commercialization of humanized monoclonal antibodies to treat Human Immunodeficiency Virus (HIV) infection. The Company's lead product candidate, PRO 140, belongs to a class of HIV therapies known as entry inhibitors that block HIV from entering into and infecting certain cells. The Company's product pipeline also includes Cytolin and CytoFeline. Cytolin is a mouse monoclonal antibody developed to identify a specific type of immune cell called a cytotoxic T cell, or cytotoxic T lymphocyte (CTL). CytoFeline is an anti-lymphocyte function-associated antigen-1 (LFA-1) antibody for the treatment of Feline Immunodeficiency Virus (FIV) infection. PRO 140 blocks HIV from entering a cell by binding to a molecule called C-C chemokine receptor type 5 (CCR5). The Company has finished Phase II clinical trials for PRO 140 with demonstrated antiviral activity in man.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: N/A
- Sub-Industry: N/A
- Symbol: NASDAQ:CYDY
- CUSIP: N/A
- Web: www.cytodyn.com
- Market Cap: $111.52 million
- Outstanding Shares: 152,763,000
- 50 Day Moving Avg: $0.71
- 200 Day Moving Avg: $0.66
- 52 Week Range: $0.46 - $1.17
Sales & Book Value:
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -4.29
- P/E Growth: 0.00
- Annual Revenue: N/A
- Price / Sales: N/A
- Book Value: ($0.01) per share
- Price / Book: -73.00
- EBIDTA: ($26,960,000.00)
- Return on Equity: -602.94%
- Return on Assets: -213.85%
- Average Volume: 178,789 shs.
Frequently Asked Questions for CytoDyn (NASDAQ:CYDY)
What is CytoDyn's stock symbol?
CytoDyn trades on the NASDAQ under the ticker symbol "CYDY."
How were CytoDyn's earnings last quarter?
CytoDyn Inc (NASDAQ:CYDY) posted its quarterly earnings data on Wednesday, October, 12th. The company reported ($0.04) EPS for the quarter, beating the Zacks' consensus estimate of ($0.05) by $0.01. View CytoDyn's Earnings History.
Where is CytoDyn's stock going? Where will CytoDyn's stock price be in 2017?
2 brokerages have issued 12-month target prices for CytoDyn's shares. Their forecasts range from $1.60 to $2.00. On average, they expect CytoDyn's stock price to reach $1.80 in the next year. View Analyst Ratings for CytoDyn.
Who are some of CytoDyn's key competitors?
Some companies that are related to CytoDyn include TOCAGEN INC (TOCA), uniQure N.V. (QURE), OVID THERAPEUTC (OVID), Quotient Limited (QTNT), NewLink Genetics Corporation (NLNK), Kindred Biosciences (KIN), Biodel (ALBO), Sientra (SIEN), Gemphire Therapeutics (GEMP), Arbutus Biopharma Corporation (ABUS), Kura Oncology (KURA), Compugen (CGEN), Cascadian Therapeutics (CASC), Madrigal Pharmaceuticals (MDGL), Foamix Pharmaceuticals (FOMX), Peregrine Pharmaceuticals (PPHM), BioDelivery Sciences International (BDSI) and Ocular Therapeutix (OCUL).
Who are CytoDyn's key executives?
CytoDyn's management team includes the folowing people:
- Anthony D. Caracciolo, Independent Chairman of the Board
- Nader Z. Pourhassan Ph.D., President, Chief Executive Officer, Director
- Michael D. Mulholland, Chief Financial Officer, Treasurer, Corporate Secretary
- Denis R. Burger Ph.D., Director
- Carl C. Dockery, Director
- Gregory A. Gould CPA, Independent Director
- A. Bruce Montgomery M.D., Independent Director
- Jordan G. Naydenov, Independent Director
How do I buy CytoDyn stock?
Shares of CytoDyn can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is CytoDyn's stock price today?
MarketBeat Community Rating for CytoDyn (NASDAQ CYDY)MarketBeat's community ratings are surveys of what our community members think about CytoDyn and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of CytoDyn stock can currently be purchased for approximately $0.73.
Consensus Ratings for CytoDyn (NASDAQ:CYDY) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||2 Buy Ratings|
|Consensus Rating:||Buy (Score: 3.00)|
|Consensus Price Target: ||$1.80 (146.58% upside)|
Analysts' Ratings History for CytoDyn (NASDAQ:CYDY)
(Data available from 7/28/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|12/14/2016||HC Wainwright||Set Price Target||Buy||$2.00||N/A|
|10/6/2016||Rodman & Renshaw||Initiated Coverage||Buy||$1.60||N/A|
Earnings History for CytoDyn (NASDAQ:CYDY)Earnings History by Quarter for CytoDyn (NASDAQ CYDY)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
Earnings Estimates for CytoDyn (NASDAQ:CYDY)
Current Year EPS Consensus Estimate: $-0.17 EPS
Next Year EPS Consensus Estimate: $-0.17 EPS
Dividend History for CytoDyn (NASDAQ:CYDY)
No dividend announcements for this company have been tracked by MarketBeat.com
Headline Trends for CytoDyn (NASDAQ:CYDY)
Latest Headlines for CytoDyn (NASDAQ:CYDY)
CytoDyn (CYDY) Chart for Friday, July, 28, 2017